Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

The FDA has approved tigecycline, the first of a new class of antimicrobial agents. The drug is a novel parenteral antibiotic that is chemically similar to minocycline. It is active against a wide variety of bacteria that cause complicated intra-abdominal and complicated skin and skin structure infections including methicillin-resistant Staphylococcus aureus (MRSA). Tigecycline is marketed by Wyeth as Tygacil™.

Pharmacology Update: Tigecycline Injection (Tygacil™)